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Introduction
Paget’s disease of bone (PDB) is a disorder of bone metabo-
lism reported to affect up to 3% of Caucasian over 55 years of
age (1). PDB is a genetically heterogeneous disorder charac-
terized by abnormal osteoclastic activity leading to bone de-
struction and macroscopic deformities, which cause bone pain
and pathological fractures. There is evidence of genetic ab-
normalities in its pathogenesis, and at least 8 different human
chromosomal loci have been correlated to PDB (2). The PDB
3 locus in chromosome 5q35-qter hosts the S Q ST M 1 / p 6 2
gene, whose mutations account for most of the sporadic 
and familial forms of PDB reported in the literature (2).
S Q S T M 1 / p 6 2 gene encodes the SQ S T M 1 / p 6 2 protein, that is
component of the NF-kB signaling pathway crucial for osteo-
clastic differentiation and activation (3). The exon 8 DNA se-
quence accounts for the ubiquitin protein-binding domain
(UBA) and represents a mutational hot spot area. An abnor-
mal UBA region is reported to account the inability to bind to
ubiquitin with consequential accumulation of sesquestosome
protein (4). Different mutations of SQSTM1/p62 have been re-
ported in French Canadian PDB families (5), and a recent ob-
servation seems to confirm the causal relationship between
this gene and Paget’s disease of bone also in sporadic Italian
patients (2).
We report a case of a family whose members are affected by
polyostotic PDB with mutation at exon 8 of SQSTM1/p62 gene.
Materials and methods
Patients
We monitored for a long period 3 members of a family affected
by polyostotic PDB at the Bone Metabolic Unit of the IRCCS
Ospedale Maggiore di Milano. The members of this family were
a woman (proband), her brother, their father and the brother’s
daughter (Fig. 1).
Brother, sister and their father were visited since 1987. Diagno-
sis of PBD was confirmed by X-rays, bone scintigraphy and
bone markers measurements. Total alkaline phosphatase (AP)
and its bone isoenzyme (BAP) were used to assess disease
activity. The woman (VB), born in 1928, is affected by polyos-
totic PBD, diagnosed in 1987, involving dorsal spine (D9, D11,
D12) and left hemipelvis. She also presented a colloid goitre
since 1989, developed in hypothyroidism in 2003 and treated
with L-thyroxin (100 mg/day). A benign M-component hyper-
gammaglobulinemia was diagnosed in 2002. VB underwent
several courses of salmon calcitonin (sCT) till 1992 and there-
after nine courses of bisphosphonates treatment (clodronate till
2001 and neridronate in 2002).
The brother (VG), born in 1942, is affected by polyostotic PBD
diagnosed in 1980 involving skull, right occipital and parietal
bone, lumbar spine (L3), left ulna and left hemipelvis. He re-
ported a traumatic lumbar spine fracture (L1) in 1972 and a
traumatic left olecranon fracture in 1980. Moreover, he under-
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Figure 1 - Pedigree of the family. Black symbols indicate the affected
PDB subjects (squares = males; circles = females). P indicates the
proband.
FOR
 REV
IEW 
ONL
Y
© CI
C ED
IZION
I INT
ERN
AZIO
NALI
went a left hemicolectomy for a dysplastic adenoma in 2001.
He was treated with several courses of sCT till 1989, and with
9 courses of clodronate thereafter.
Their father, born in 1901, had also polyostotic PBD, involving
right proximal homerus, pelvis and proximal distal femoral epi-
physis. He suffered ictus cerebri in 1986 with right hemiparesis.
For PDB he underwent a single course of i.m. sCT for 4
months in 1987. He died in 1992 consequently to PDB’s car-
diovascular complication.
VG’s daughter (VS), born in 1981, is not affected by PDB.
Treatment
In all patients pharmacological treatment was prescribed when
serum AP and BAP levels firstly increased at least 25% above
the upper limit of the normal range. During the whole observa-
tion period we used in these PDB patients synthetic sCT at the
dosage of 100 UI i.m/day for 6 months and bisphosphonates
(clodronate, 300 mg i.v./day for 5 days, and neridronate, 100
mg/day i.v. for 2 days). As regards sCT, another course of
treatment was prescribed after the sixth month of follow-up
when total serum AP activity newly increased above the upper
limit of the normal range by at least 25%.
Overall, regarding bisphosphonates therapy, we have treated
about 50 PDB outpatients. The nadir of our patients’ serum AP
and BAP levels were observed between the third and the fifth
month after therapy and the zenith usually after the ninth
month (data not published). Disease activity was evaluated by
the means of serum total AP and BAP determined at three, five,
and nine months after therapy. Another course of drugs was
prescribed when, after the ninth month, total serum AP and
BAP had an increase of at least 25% above the upper limit of
the normal range. After 5 months of treatment with clodronate,
the patients showing serum AP and BAP above the upper limit
of the normal range, although exhibiting a reduction of their val-
ues to 50% or more of the pre-treatment value, were classified
as not responders to the therapy and switched to neridronate.
Mutational analysis
Genetic tests were performed in the affected patients VB and
VG, and in VS, not affected. Genetic tests of their father were
not possible, because the study started ten years after his
death and no biological samples were available.
After administration of an informed consent form approved by
the Local Ethical Committee, peripheral blood was obtained
and genomic DNA was extracted using a microvolume extrac-
tion method, QIAamp DNA Mini Kit (Qiagen GmbH, Hilden,
Germany), according to the manufacturer’s instructions.
PCR protocol was performed as follows. Exons 7 and 8 of the
SQSTM1/p62 gene were amplified by PCR (I-Cycler, Bio-Rad
Laboratories, Milan, Italy) using two couples of primers located
in the flanking introns: respectively 5’-GACTGTCT-
GCCAGGAGCC–3’/5’-CCCTGCAGTGGAGAACATCT-3’ for
exon 7 and 5’-CAGTGTGGCCTGTGAGGAC-3’/5’-CAGT-
GAGCCTTGGGTCTCG-3’ for exon 8. For each patient we
used 0.1 mg of DNA, in a final buffer volume of 50 ml [67 mM
Tris-HCl, 16.6 mM (NH4)SO4, 0.01% Tween-20, 1.5 mM MgCl2,
0.2 mM deoxyribonucleotides, 0.2 mM of each primer and one
unit of Polytaq (Polymed, Florence, Italy)]. Thirty-five PCR cy-
cles were performed at 94 °C for 30 seconds, 58 °C (exon 7) or
55 °C (exon 8) for 30 seconds and 72 °C for 1 minute, after a
first denaturing cycle at 94 °C for 3 minutes. A final extension
cycle of 5 minutes at 72 °C was performed.
PCR products were tested by 2% ethidium bromide-stained
agarose gel electrophoresis, purified using the High Pure PCR
Product Purification Kit (Roche, Indianapolis, IN, USA) and fi-
nally sequenced using the BigDye Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystems, Foster City, CA, USA). The
sequencing reaction consisted of twenty-five repeated cycles of
denaturation for 10 seconds at 96 °C, annealing for 5 seconds
at 55 °C and extension for 2 minutes at 60 °C. The sequencing
products were purified with DyeEx 2.0 Spin Kit (Quiagen,
GmbH, Hilden, Germany) to remove the excess of dye termina-
tor. Five microliters of each purified sequence were then resus-
pended in 15 ml of formamide and denaturated for 2 minutes at
95 °C. Analysis of the forward and reverse sequences was per-
formed on the ABI Prism 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA). The sequences obtained
were compared to reference sequence NM_003900.
Results
Mutational screening of the exons 7 and 8 of the SQSTM1/p62
gene revealed the presence of a C/T transversion at position
1215 in exon 8 (Fig. 2) in the affected individuals (VB and VG).
This mutation causes the substitution proline/leucine at codon
392 (P392L), and it has been described by other reports in dif-
ferent populations (2, 5-10). No mutation was found in the not
affected subject VS.
Discussion
The aminoacidic residue 392 was conserved in the mouse and
rat homologues. The P392 residue is located in the C-terminal
end of the p62 protein flanking the ubiquitin associated domain
(UBA) and could thus be important for the conformation and/or
function of this region. The UBA domain of SQSTM1/p62 consists
of three anti-parallel a -helices; P392 is the first residue of helix 1.
P392L mutation modifies the secondary structure of the UBA do-
main by extending the N-terminus of helix 1, and this could result
in an altered conformation and/or function of p62 protein (11).
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Figure 2 - SQSTM1 gene mutation (bottom) detected in two Italian PDB
patients from the same family. Specific forward and reverse sequences
have been reported. Arrows indicate the presence of mutation, a C>T
transition at exon 8.
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However, the molecular mechanisms by which SQSTM1/p62
UBA domain mutations cause PDB remain undetermined. The
ubiquitination pathway plays a crucial role in the regulation of
signal transduction by targeting key components for degrada-
tion by proteasome. It is possible that mutations in the UBA do-
main of SQSTM1/p62 result in an accumulation of signaling in-
termediates in cytosol that are involved in the regulation of os-
teoclastogenesis and/or osteoclast activation such as NF-k B
(8). Further studies will be required to elucidate the exact
mechanism involved.
The report of two novel mutations, other than P392L, at exon 8
of the SQSTM1/p62 gene in sporadic Italian PDB patients by
Falchetti et al. (2) confirms the evidence of a clustered muta-
tional area at this level also in PDB patients of Italian origin, in-
dicating the role of the UBA domain in the biological properties
of SQSTM1/p62 protein. Mutational analysis of these subjects
provided the opportunity to demonstrate the co-segregation of
P392L mutation and PDB trait.
Data about this PDB family strongly confirm the importance of
genetic analysis in order to early identify asymptomatic carri-
ers, making possible to prevent or limit the occurrence of PDB.
The creation of a large S Q S T M 1 / p 6 2 Italian mutational data-
base, together with functional studies, will provide the opportu-
nity to assess a possible correlation between the type of muta-
tion and the response to therapy, as well as to set-up new ther-
apeutic strategies.
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